{"article_title": "New and Costly Cholesterol Drugs Could Soon Debut", "article_keywords": ["physician", "pcsk9", "costly", "statinintolerant", "drugs", "debut", "soon", "receptors", "inhibitors", "likely", "cholesterol", "protein", "patients", "davidson"], "article_url": "http://www.hcplive.com/medical-news/new-and-costly-cholesterol-drugs-could-soon-debut", "article_text": "New and Costly Cholesterol Drugs Could Soon Debut\n\nPhysicians are likely to get 2 new weapons to treat dyslipidemia by mid-summer: the first 2 PCSK9 inhibitors, both monoclonal antibodies, are expected to be approved by the US Food and Drug Administration.Speaking at the 19Annual Conference on Hypertension, Diabetes and Dyslipidemia, Michael Davidson, MD, a clinical professor and director of preventive cardiology at the University of Chicago\u2019s Pritzker School Medicine, offered a primer on the highly anticipated new drugs.Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a complex protein created by the liver that then goes into the plasma. \u201cWhen the liver takes in LDL receptors PCSK9 comes along as an obnoxious passenger,\u201d Davidson said.The discovery that PCSK9 inhibits LDL receptors was made in France.Validation that it was safe to inhibit the protein came in Dallas, TX, when a patient was found to have lost her ability to produce PKSC9 but had no ill effects.\u201cThe word is the first two PCSK9 inhibitors will be available by fall,\u201d he said.\u201cThis could be very important to primary care,\u201d Davidson said.But in answer to a physician who wondered whether the average family practice physician would be reimbursed by insurers for the drugs\u2014which are likely to be expensive\u2014Davidson said it was hard to predict. By one estimate, the drugs will cost between $7,000 and $12,000 for a year\u2019s treatment.The drugs will be administered by injection, likely a self-injector, likely 1 every 2 weeks.Patients who are statin-intolerant, or who have familial hypercholesterolemia are good candidates for the new drugs.\u201cI\u2019m confident they have a good safety profile,\u201d he said, and equally promising, \u201cwe are seeing a 50% lowering of cardiac events\u2014but the numbers [of patients in trials] are low still.\u201dPhysicians will have to call on their experience and judgement to decide when patients are truly statin-intolerant, he said.\u201cStatin-intolerance is a flaky thing\u2014academics are not sure it is real and say it\u2019s not been proven,\u201d Davidson noted, \u201cbut we believe it is.\u201dThree pharmaceutical companies\u2014Amgen, Sanofi/Regeneron, and Pfizer have PCSK9 inhibitors advancing in the pipeline.", "article_metadata": {"description": "The medical world is eagerly awaiting the likely approval this summer of two new cholesterol-lowering drugs, known as PCSK9 inhibitors. But at a cost of $7,000 to $12,000 a year, they won't be for everyone.", "og": {"site_name": "MD Magazine", "description": "The medical world is eagerly awaiting the likely approval this summer of two new cholesterol-lowering drugs, known as PCSK9 inhibitors. But at a cost of $7,000 to $12,000 a year, they won't be for everyone.", "title": "New and Costly Cholesterol Drugs Could Soon Debut", "url": "http://www.hcplive.com/medical-news/new-and-costly-cholesterol-drugs-could-soon-debut", "image": "https://s3.amazonaws.com/hcplive/v1_media/_upload_image/_thumbnails/cholesterol.jpg", "type": "Article"}, "msapplication-TileColor": "#ffffff", "msapplication-TileImage": "https://s3.amazonaws.com/hcplive/v2_media/_core/favi/ms-icon-144x144.png", "keywords": "primary care, family practice, internal medicine, cardiology, lipids, cholesterol", "theme-color": "#ffffff"}, "_id": "\"57477af36914bd0286fd3318\"", "article_summary": "New and Costly Cholesterol Drugs Could Soon DebutPhysicians are likely to get 2 new weapons to treat dyslipidemia by mid-summer: the first 2 PCSK9 inhibitors, both monoclonal antibodies, are expected to be approved by the US Food and Drug Administration.Speaking at the 19Annual Conference on Hypertension, Diabetes and Dyslipidemia, Michael Davidson, MD, a clinical professor and director of preventive cardiology at the University of Chicago\u2019s Pritzker School Medicine, offered a primer on the highly anticipated new drugs.Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a complex protein created by the liver that then goes into the plasma.\n\u201cWhen the liver takes in LDL receptors PCSK9 comes along as an obnoxious passenger,\u201d Davidson said.The discovery that PCSK9 inhibits LDL receptors was made in France.Validation that it was safe to inhibit the protein came in Dallas, TX, when a patient was found to have lost her ability to produce PKSC9 but had no ill effects.\u201cThe word is the first two PCSK9 inhibitors will be available by fall,\u201d he said.\u201cThis could be very important to primary care,\u201d Davidson said.But in answer to a physician who wondered whether the average family practice physician would be reimbursed by insurers for the drugs\u2014which are likely to be expensive\u2014Davidson said it was hard to predict.\nBy one estimate, the drugs will cost between $7,000 and $12,000 for a year\u2019s treatment.The drugs will be administered by injection, likely a self-injector, likely 1 every 2 weeks.Patients who are statin-intolerant, or who have familial hypercholesterolemia are good candidates for the new drugs.\u201cI\u2019m confident they have a good safety profile,\u201d he said, and equally promising, \u201cwe are seeing a 50% lowering of cardiac events\u2014but the numbers [of patients in trials] are low still.\u201dPhysicians will have to call on their experience and judgement to decide when patients are truly statin-intolerant, he said.\u201cStatin-intolerance is a flaky thing\u2014academics are not sure it is real and say it\u2019s not been proven,\u201d Davidson noted, \u201cbut we believe it is.\u201dThree pharmaceutical companies\u2014Amgen, Sanofi/Regeneron, and Pfizer have PCSK9 inhibitors advancing in the pipeline."}